Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-04-11 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Cleansing Statement 1 page 166.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Cleansing Notice Under Section 708A(5)(E) of the Corporations Act'. It details the issuance of 250,000 fully paid ordinary shares and compliance statements under the Corporations Act. The content focuses on a regulatory notice related to share issuance without disclosure and compliance with legal provisions. The document length is short (1343 characters) and it does not contain financial statements or detailed financial data. It is not a full report but a regulatory announcement about share issuance and compliance. Therefore, it fits best under the category 'Regulatory Filings' (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-04-11 English
Anti-Viral Patent Granted in Hong Kong 2 pages 233.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals Limited about the granting of an anti-viral patent in Hong Kong. It discusses intellectual property rights, patent details, and the company's development strategy. There is no financial data, no mention of quarterly or annual results, no management changes, no voting results, no legal proceedings, and no regulatory certifications. The document is a corporate announcement about intellectual property and business development rather than a financial report or regulatory filing. The length is 3695 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-04-10 English
Application for quotation of securities - RCE 6 pages 27.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Recce Pharmaceuticals Ltd regarding the quotation of securities issued due to options being exercised or convertible securities being converted. It details the number and type of securities to be quoted, issue dates, prices, and the resulting issued capital. The content is focused on the issuance and quotation of new shares following conversion of options, which is a capital structure change. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive details about the securities issued. This fits the definition of a Share Issue/Capital Change announcement.
2022-03-31 English
Cleansing Statement 1 page 164.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Cleansing Notice Under Section 708A(5)(E) of the Corporations Act'. It details the issuance of 250,000 fully paid ordinary shares and compliance statements under the Corporations Act. The document is short (1342 characters) and serves as a regulatory notice about share issuance without disclosure under specific legal provisions. It does not contain financial statements, management discussion, or detailed financial data. It is an announcement related to capital issuance and compliance, fitting the category of Capital/Financing Update (CAP).
2022-03-31 English
Positive safety data from 4th Cohort -Phase I Clinical Trial 3 pages 256.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement reporting positive safety data from the fourth cohort of a Phase I clinical trial for a drug candidate. It provides highlights, trial details, and company background. The text is relatively short (4297 characters) and focuses on clinical trial progress and safety data rather than comprehensive financial or operational reporting. It does not contain full financial statements, detailed management discussion, or regulatory certifications. It is an announcement of clinical trial results, which fits best under a general regulatory announcement category rather than a formal financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-03-29 English
$3.08m R&D Rebate Received 2 pages 246.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals Ltd dated 28 March 2022. It announces the receipt of a cash Research and Development Tax Incentive rebate from the Australian Tax Office for the year ending 30 June 2021. The content focuses on the receipt of government funding related to R&D activities and includes no financial statements, detailed financial results, or management discussion. The document is relatively short (3248 characters) and serves as a formal announcement of a specific financial event (receipt of R&D rebate). It does not contain comprehensive financial data or analysis that would classify it as an Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. Therefore, the best fitting category is a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2022-03-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.